PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Two-Pill attack on tough ovarian cancers
Disease control OngoingThis study is testing a combination of two oral drugs, olaparib and cediranib, to see if they can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is for women whose cancer has returned after previous treatment. The main goals are to see if the dru…
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC